RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial

RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial

Abstract Background Over 12,000 new cases of B-cell malignancies are diagnosed in the UK each year, with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) being the most common subtypes. Standard frontline therapy consists of immunochemotherapy with a CD20 monoclonal antibody (mAb),...

Full description

Bibliographic Details
Main Authors: Sean H. Lim, Kim M. Linton, Graham P. Collins, Joke Dhondt, Joshua Caddy, Liz Rossiter, Karan Vadher, Keira Fines, Laura E. Rogers, Diana Fernando, Louise Stanton, Andrew J. Davies, Peter W. M. Johnson, Gareth Griffiths
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Trials
Subjects:
lymphoma
B-cell malignancy
varlilumab
rituximab
CD20
CD27
Online Access:http://link.springer.com/article/10.1186/s13063-018-2996-6

Internet

http://link.springer.com/article/10.1186/s13063-018-2996-6

Similar Items